Actively Recruiting
FDG-PET in the Diagnosis of Autoimmune Encephalitis
Led by University of Milano Bicocca · Updated on 2026-03-24
90
Participants Needed
6
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This observational study evaluates brain metabolism patterns in patients with autoimmune encephalitis using fluorodeoxyglucose-positron emission tomography (FDG-PET). Researchers aim to identify if there is a specific metabolic pattern in these patients compared to normal controls and those with Alzheimer's disease. Data and images will be collected retrospectively from hospital records, with controls selected from public databases. The study involves analyzing brain FDG-PET images from patients diagnosed with autoimmune encephalitis who underwent this imaging during their disease course. Statistical parametric mapping (SPM) will be used to analyze the brain metabolic patterns. The main focus is on comparing the metabolic activity up to 6 months after imaging. Participants' medical records, including MRI, cerebrospinal fluid analysis, autoantibody testing, and FDG-PET scans performed between clinical presentation and treatment, will be reviewed. Researchers will assess brain metabolism patterns, sensitivity of basal ganglia hypermetabolism, and diagnostic delay. Consent is required for participation. The study is observational and retrospective, with no treatment intervention involved.
CONDITIONS
Brief Title
FDG-PET in the Diagnosis of Autoimmune Encephalitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of autoimmune encephalitis according to clinical criteria
- Brain magnetic resonance imaging performed between clinical presentation and treatment
- Cerebrospinal fluid analysis performed between clinical presentation and treatment
- Brain FDG-PET performed between clinical presentation and treatment
- Autoantibodies testing performed between clinical presentation and treatment
You will not qualify if you...
- Refusal to give consent for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Between clinical presentation and treatment
Participants undergo a brain FDG-PET scan to evaluate brain metabolic patterns as part of diagnosing autoimmune encephalitis.
1 visit (in-person) for FDG-PET scan
Duration - Up to 6 months
Participants are monitored for up to 6 months to assess brain metabolic patterns and diagnostic outcomes.
Visits as needed for follow-up assessments
Trial Site Locations
Total: 6 locations
1
Azienda Sanitaria Universitaria Friuli Centrale
Udine, Friuli Venezia Giulia, Italy
Not Yet Recruiting
2
IRCCS Ospedale Policlinico San Martino
Genoa, Liguria, Italy
Not Yet Recruiting
3
Fondazione IRCCS Mondino
Pavia, Lombardy, Italy
Actively Recruiting
4
Fondazione IRCCS Istituto Neurologico "Carlo Besta"
Milan, Milano, Italy, 20133
Not Yet Recruiting
5
Ospedale San Paolo
Milan, Milano, Italy, 20142
Not Yet Recruiting
6
Fondazione IRCCS San Gerardo dei Tintori
Monza, Monza e Della Brianza, Italy, 20900
Actively Recruiting
Research Team
S
Simone Beretta, MD, PhD
F
Federico Emanuele Pozzi, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here